Drug Trial Radar · NCT00176930
Stem Cell Transplant for Hematological Malignancy
Last checked: Nov 19, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
330
Actual
Start
Oct 2001
Primary completion
Dec 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Conditions
- Leukemia, Myeloid, Chronic
- AML
- Leukemia, Lymphocytic, Acute
- MDS
- Leukemia, Lymphocytic, Chronic
- JMML
- Hodgkin's Disease
- Non-hodgkin's Lymphoma
- Multiple Myeloma
Interventions
Stem Cell TransplantBiological
Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
CyclophosphamideDrug
60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
Total Body IrradiationRadiation
On Day -4, -3, -2, -1 total body irradiation is given twice daily.
BusulfanDrug
When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
Equine ATG (ATGAM)Drug
UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
CD4+/CD25+ cellsBiological
On days -2, patients will receive CD4+/CD25+ cells intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Disease-Free Survival at 2 Years Post TransplantTime frame: 2 years
- Number of Participants Experiencing Disease-Free Survival at 5 Years Post TransplantTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.